CorMedix (CRMD) director Myron Kaplan awarded 30,453 RSUs in new grant

Rhea-AI Filing Summary

CorMedix Inc. director Myron Kaplan received an equity grant of 30,453 restricted stock units on January 26, 2026. The Form 4 shows these RSUs were awarded at a price of $0.00 per unit and will vest in full on January 26, 2027, subject to his continued service through that date.

Following this grant, Kaplan directly beneficially owned 231,487 shares of CorMedix common stock. The filing also notes additional indirect holdings of 20,000 shares held by his spouse and 10,000 shares held by his spouse as guardian for grandchildren, for which he expressly disclaims beneficial ownership.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Kaplan Myron

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	30,453	$0.00	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 231,487 shares (Direct); Common Stock — 20,000 shares (Indirect, Spouse)

Footnotes (1)

1. These shares represent restricted stock units issued on January 26, 2026. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. These restricted stock units will vest in full on January 26, 2027, subject to continued service on the vesting date. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaplan Myron

(Last) (First) (Middle)

C/O CORMEDIX INC.

389 INTERPACE PKWY, SUITE 450

(Street)

PARSIPPANY NJ 07054

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [ CRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/26/2026		A		30,453	A	$0.00(1)	231,487	D
Common Stock								20,000(2)	I	Spouse
Common Stock								10,000(2)	I	Spouse as Guardian for Grandchildren

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares represent restricted stock units issued on January 26, 2026. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. These restricted stock units will vest in full on January 26, 2027, subject to continued service on the vesting date.

2. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Beth Zelnick Kaufman, attorney-in-fact	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CorMedix Inc. (CRMD) report for Myron Kaplan?

CorMedix reported that director Myron Kaplan received 30,453 restricted stock units on January 26, 2026. These equity awards were granted at $0.00 per unit and will convert into an equal number of common shares if he remains in service through the January 26, 2027 vesting date.

How many CorMedix (CRMD) shares does Myron Kaplan directly own after this Form 4?

After the reported grant, Myron Kaplan directly beneficially owned 231,487 shares of CorMedix common stock. This figure reflects his direct holdings only and excludes additional shares reported as indirectly held by his spouse and spouse as guardian, which he disclaims beneficial ownership of.

When do Myron Kaplan’s newly granted CorMedix (CRMD) RSUs vest?

The 30,453 restricted stock units granted to Myron Kaplan vest in full on January 26, 2027. Vesting is contingent on his continued service through that date, at which point each RSU is scheduled to convert into one share of CorMedix common stock.

What indirect CorMedix (CRMD) share holdings are associated with Myron Kaplan?

The Form 4 lists 20,000 CorMedix shares held by his spouse and 10,000 shares held by his spouse as guardian for grandchildren. Kaplan disclaims beneficial ownership of these indirectly held securities, meaning he does not concede that he is their beneficial owner for regulatory purposes.

Does Myron Kaplan’s CorMedix (CRMD) Form 4 involve any stock sales?

The filing reports only an acquisition of 30,453 restricted stock units at $0.00 per unit and no sales of CorMedix shares. It is a compensatory equity grant that increases his direct beneficial holdings rather than a disposition of stock into the market.

What does it mean that Myron Kaplan disclaims beneficial ownership of certain CorMedix (CRMD) shares?

By disclaiming beneficial ownership, Kaplan states he should not be treated as the beneficial owner of the shares held by his spouse and by his spouse as guardian for grandchildren. This legal language clarifies his position regarding control or economic interest for Section 16 reporting purposes.